Pharma in Brief
JULY 19, 2023
CADTH Time-Limited Reimbursement Recommendations Starting in the fall of 2023, CADTH, which conducts health technology assessments ( HTAs ) to inform public insurers, will introduce time-limited reimbursement recommendations for certain drug products. The deadline to provide input is August 18, 2023.
pharmaphorum
JANUARY 28, 2021
Pharmacists have more insight into a patient’s insurance coverage than most providers, so this change could create a lot of value for patients throughout the country. We didn’t anticipate seeing interchangeability for biosimilars until 2023, when several biosimilars referencing Humira are slated to come market.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Big Molecule Watch
AUGUST 25, 2023
The Inflation Reduction Act’s Medicare Drug Price Negotiation Program will kick off next week. There are reports that the White House may announce the list of selected drugs even before that deadline, on Tuesday, August 29 th. Before the IRA, the government could not set prices for any drugs covered by Medicare.
Putting Patients First Blog
DECEMBER 13, 2023
NHC 2024 Policy Priorities December 13, 2023 By: Allen Pinn, Coordinator, Policy The National Health Council (NHC) prides itself in providing a voice for the over 160 million people living with a chronic disease or disability and their caregivers. In 2023, the NHC continued its leadership in the health care space.
Proxsys Rx
AUGUST 16, 2023
“Don’t believe drug companies: 340B is a program worth saving” On Tuesday, August 8, The Hill published a guest editorial (title above) by John Hassell — national director of advocacy at the AIDS Healthcare Foundation (AHF). First, start with presenting drug company-funded research as if it is non-biased.
Expert insights. Personalized for you.
40 
Let's personalize your content